Extended Ambulatory Monitoring Improves Risk Stratification in Hypertrophic Cardiomyopathy

NCT03182153 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 83

Last updated 2018-06-27

No results posted yet for this study

Summary

Eligible subjects will wear 4 consecutive external monitoring devices for a total of 28 days of monitoring.

Conditions

Interventions

DEVICE

Extended Cardiac Monitoring

Extended External Cardiac Monitoring

Sponsors & Collaborators

  • Atlantic Health System

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2018-12-28
Completion
2018-12-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03182153 on ClinicalTrials.gov